Yi Zhong

Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma

Michael J. Harvey, Yi Zhong, Eric Morris et al. · PLoS ONE · 2022 · 31 citations · Full text

Pharmacy, Internal Medicine, Pharmacoeconomics +17

Disease Progression Stages and Burden in Patients with Duchenne Muscular Dystrophy Using Administrative Claims Supplemented by Electronic Medical Records

Joel Iff, Yi Zhong, Deepshekhar Gupta et al. · Advances in Therapy · 2022 · 26 citations

Computing, Biomedical Informatics, Health Informatics +14

Survival among patients receiving eteplirsen for up to 8 years for the treatment of <scp>Duchenne</scp> muscular dystrophy and contextualization with natural history controls

Joel Iff, Nicolae Done, Edward Tuttle et al. · Muscle & Nerve · 2024 · 25 citations · Full text

Public Health, Internal Medicine, Pharmacotherapy +15

Delays in pulmonary decline in eteplirsen‐treated patients with <scp>Duchenne</scp> muscular dystrophy

Joel Iff, C. Gerrits, Yi Zhong et al. · Muscle & Nerve · 2022 · 22 citations · Full text

Medicine, Biostatistics, Pharmacotherapy +13

Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA

Joel Iff, Yi Zhong, Edward Tuttle et al. · Journal of Comparative Effectiveness Research · 2023 · 11 citations · Full text

Pharmacy, Pharmacoeconomics, Health Services Research +16